Pioneers Honored for Transforming Liver Cancer Survival

LOS ANGELES, CA – April 08, 2026 – In a tribute to two of the most influential figures in modern liver cancer treatment, Blue Faery: The Adrienne Wilson Liver Cancer Association has awarded its 2026 Award for Excellence in Liver Cancer Research to Dr. Richard Finn and Dr. R. Kate Kelley. Dr. Finn receives the Lifetime Impact Award, while Dr. Kelley is recognized with the Clinical Leadership and Patient Impact Award for their transformative contributions to the field.

The announcement, made on what would have been the 40th birthday of Adrienne Wilson, for whom the association is named, highlights a paradigm shift in the fight against hepatocellular carcinoma (HCC), the most common form of primary liver cancer. For years, patients with advanced HCC faced a grim prognosis with limited treatment options. The pioneering work of Drs. Finn and Kelley has been instrumental in developing and validating new therapies that have dramatically improved survival rates and established new standards of care worldwide.

"Drs. Finn and Kelley have helped transform the landscape of liver cancer care," said Andrea Wilson Woods, founder and president of Blue Faery. "Their leadership, innovation, and dedication to patients continue to move the field forward and inspire hope for families facing HCC."

The Architects of a New Standard of Care

Dr. Richard Finn, a Professor of Medicine at UCLA's David Geffen School of Medicine, has been a central figure in nearly every major therapeutic breakthrough for HCC in the last decade. His Lifetime Impact Award acknowledges a career dedicated to translating complex biology into life-extending treatments.

Perhaps his most significant contribution was leading the research that established the combination of atezolizumab (an immunotherapy agent) and bevacizumab (a targeted therapy) as the new first-line standard of care for advanced HCC. This regimen was the first in over a decade to demonstrate a significant survival advantage over the previous standard, sorafenib. Clinical trial data showed that the combination extended median overall survival to 19.2 months, compared to 13.2 months for sorafenib, giving patients precious additional time.

Beyond this landmark achievement, Dr. Finn’s influence is woven into the fabric of modern HCC treatment. He was a key investigator in the development of lenvatinib, providing patients with another effective first-line option, and led the clinical studies that secured FDA approval for regorafenib, a crucial second-line therapy for patients whose cancer progresses. His work has effectively built a multi-layered therapeutic strategy where previously there was only a single road with a dead end.

Personalizing the Fight, Patient by Patient

Receiving the Clinical Leadership and Patient Impact Award, Dr. R. Kate Kelley, a Professor of Clinical Medicine at the University of California, San Francisco (UCSF), is celebrated for her dedication to refining treatment through clinical innovation and a focus on the individual patient. Her work embodies the push toward precision oncology in a disease known for its complexity and heterogeneity.

Dr. Kelley specializes in cancers of the liver and bile duct, leading numerous clinical trials for novel therapies. Her research was instrumental in the approval of cabozantinib, a tyrosine kinase inhibitor that provides another vital option for HCC patients who have progressed on initial treatments. This work has helped expand the arsenal of effective drugs, ensuring more patients have a chance at a subsequent line of therapy.

What truly distinguishes Dr. Kelley’s impact is her focus on translational research and biomarkers. She leads efforts to identify the molecular and genetic signatures within tumors that can predict which patients will respond to specific treatments. This pursuit of personalized medicine aims to move beyond a one-size-fits-all approach, tailoring therapies to maximize effectiveness and minimize toxicity for each person. By leading the UCSF Hepatobiliary Tissue Bank and serving on national guideline panels like the NCCN, she is not only treating patients today but is actively building the framework for a more precise and effective future.

The Power of Advocacy and Partnership

The awards shine a light not only on the researchers but also on the vital ecosystem that supports them. Blue Faery, the organization bestowing the honor, was born from the personal tragedy of its founder, Andrea Wilson Woods, whose sister Adrienne died of liver cancer at 15. This deeply personal mission fuels the organization's patient-centric approach. With a Four-Star rating from Charity Navigator, Blue Faery has proven highly effective in its mission.

The organization provides crucial resources, including free, comprehensive Patient Resource Guides distributed to over 700 treatment centers across the United States and internationally. Its private online Liver Cancer Community offers a safe, HIPAA-compliant space for patients and caregivers to connect and find support. These programs address the profound need for reliable information and community in the face of a devastating diagnosis.

This year's award, funded by the pharmaceutical company AstraZeneca, also underscores the critical role of public-private partnerships in accelerating medical progress. AstraZeneca is itself a major contributor to the HCC treatment landscape, having developed the dual immunotherapy regimen of durvalumab and tremelimumab, another preferred first-line treatment. Such collaborations between advocacy groups, academic researchers, and industry are essential for funding research, running large-scale clinical trials, and ultimately bringing new drugs from the lab to the clinic.

A New Horizon in a Formidable Battle

Despite the monumental progress driven by individuals like Drs. Finn and Kelley, hepatocellular carcinoma remains a formidable global health challenge. It is a leading cause of cancer-related death, often diagnosed at an advanced stage when curative options like surgery or transplantation are no longer possible. Furthermore, the inherent biological diversity of HCC means that even the best available therapies do not work for everyone, and treatment resistance is a constant hurdle.

The future of the fight against liver cancer lies in overcoming these challenges through continued innovation. The field is rapidly moving toward hyper-personalized medicine, driven by the search for reliable biomarkers. Researchers are intensely focused on developing liquid biopsies—simple blood tests that can detect circulating tumor DNA (ctDNA)—to enable earlier diagnosis, monitor treatment response in real-time, and identify resistance mechanisms as they emerge.

The therapeutic pipeline is also expanding into novel territories. Scientists are exploring next-generation immunotherapies that target different immune pathways, such as TIM3 and TIGIT, to overcome resistance to current agents. Entirely new modalities, including CAR-T cell therapies that engineer a patient's own immune cells to attack the cancer, and oncolytic viruses designed to selectively infect and destroy tumor cells, are being investigated in clinical trials. The work of today's awardees has built a strong foundation, creating a new platform from which this next wave of innovation can be launched, offering ever-increasing hope to patients and families affected by liver cancer.